



医渡科技 4 月通讯 | 2025 年

## Yidu Tech Events in April 2025

### 集团亮点

#### Business Update

医渡科技与北京友谊医院达成全面战略合作，共建临床科研数智实验室

#### **Yidu Tech Forms Comprehensive Strategic Partnership with Beijing Friendship Hospital to Jointly Establish a Clinical Research Intelligence Laboratory**

在“推动创新 凝聚人才 发展新质生产力”院士讲堂暨北京友谊医院医学数智创新中心揭牌仪式上，医渡科技与北京友谊医院签署战略合作协议，双方将联合共建“临床科研数智实验室”，聚焦大模型技术在医学研究中的深度应用，致力于解决临床科研效率低、患者招募难、成果转化慢三大痛点，打造“数智驱动”的医疗创新标杆。

中国科学院院士胡事民，中国工程院院士吴世忠，首都医科大学党委副书记、校长、中国工程院院士吉训明，北京市卫生健康委党委委员、副主任严进，北京经开区管委会副主任刘力，以及北京友谊医院党委书记谢向辉，北京友谊医院党委副书记、院长张澍田，北京友谊医院党委常委、副院长、中国工程院院士、医学数智创新中心主任王振常等多位领导及嘉宾出席活动。

At the "Academician Forum on Promoting Innovation, Gathering Talent, and Developing New-Quality Productive Forces" and the unveiling ceremony of the Beijing Friendship Hospital Medical Intelligence Innovation Center, Yidu Tech and Beijing Friendship Hospital signed a strategic cooperation agreement. The two parties will jointly establish a "Clinical Research Intelligence Laboratory," focusing on the in-depth application of large language model technologies in medical research. The initiative aims to address three key challenges in clinical research: low efficiency, difficulty in

patient recruitment, and slow transformation of research outcomes - ultimately creating a benchmark for AI-driven medical innovation.

The event was attended by Hu Shimin, Academician of the Chinese Academy of Sciences; Wu Shizhong, Academician of the Chinese Academy of Engineering; Ji Xunming, Vice Party Secretary and President of Capital Medical University and Academician of the Chinese Academy of Engineering; Yan Jin, Party Committee Member and Deputy Director of the Beijing Municipal Health Commission; Liu Li, Deputy Director of the Beijing Economic-Technological Development Area; Xie Xianghui, Party Secretary of Beijing Friendship Hospital; Zhang Shutian, Vice Party Secretary and President of Beijing Friendship Hospital; and Wang Zhenchang, Party Committee Member, Vice President of Beijing Friendship Hospital, Academician of the Chinese Academy of Engineering, and Director of the Medical Digital Intelligence Innovation Center.



医渡科技徐济铭出席清华公卫与健康高质量发展大会，分享如何以 AI 赋能公卫新范式  
**Yidu Tech CEO Xu Jiming Attended Tsinghua Public Health & Wellness High-**



## **Quality Development Conference, Sharing Insights on AI-Driven Public Health Paradigms**

清华大学举办“弦歌五载，筑梦卫来——公共卫生与健康高质量发展大会”，医渡科技联合创始人、CEO 徐济铭受邀发表《AI 赋能公共卫生新范式》主题演讲，系统阐述了人工智能技术如何驱动公共卫生体系创新，并分享了医渡科技在传染病监测预警、慢病管理及全球化实践中的前沿探索与成果。

开幕式上，清华大学校长、中国科学院院士李路明，国家卫生健康委员会副主任、中国科学院院士曾益新，国家卫生健康委员会副主任、国家疾病预防控制局局长、中国工程院院士沈洪兵，北京市委常委、副市长靳伟，中国工程院副院长、中国医学科学院(北京协和医学院)院校长、中国工程院院士王辰，香港科技大学校长、中国科学院院士叶玉如，华中科技大学同济医学院院长、中国工程院院士邬堂春，清华大学万科公共卫生与健康学院院长陈冯富珍等重量级嘉宾致辞。

Tsinghua University hosted the "Five Years of Progress, Building the Future of Public Health" High-Quality Development Conference on Public Health and Wellness, where Xu Jiming, Co-founder and CEO of Yidu Tech, was invited to deliver a keynote speech titled "AI Empowering a New Paradigm in Public Health." In his presentation, Xu systematically explained how artificial intelligence can drive innovation in public health systems and shared Yidu Tech's cutting-edge work and achievements in areas such as infectious disease surveillance and early warning, chronic disease management, and global implementation.

At the opening ceremony, distinguished guests delivered speeches, including Li Luming, President of Tsinghua University and Academician of the Chinese Academy of Sciences; Zeng Yixin, Vice Minister of the National Health Commission and Academician of the Chinese Academy of Sciences; Shen Hongbing, Vice Minister of the National Health Commission, Director of the National Disease Control and Prevention Administration, and Academician of the Chinese Academy of Engineering; Jin Wei, Standing Committee Member of the Beijing Municipal Committee and Vice Mayor of Beijing; Wang Chen, Vice President of the Chinese Academy of Engineering,



President of the Chinese Academy of Medical Sciences (Peking Union Medical College), and Academician of the Chinese Academy of Engineering; Ye Yuru, President of the Hong Kong University of Science and Technology and Academician of the Chinese Academy of Sciences; Wu Tangchun, Dean of Tongji Medical College of Huazhong University of Science and Technology and Academician of the Chinese Academy of Engineering; and Margaret Chan Fung Fu-chun, Dean of Tsinghua University Vanke School of Public Health.



医渡科技出席未来 XDC 新药大会，以技术革新构建智能新药研发“中国样本”

### **Yidu Tech Attended Future XDC New Drug Conference, Showcasing a "China Model" for Intelligent Drug R&D Through Technological Innovation**

以“In China, For Global”为主题的“2025 未来 XDC 新药大会”在成都召开，医渡科技联合创始人、CEO 徐济铭受邀发表了“基于大模型的全流程智能化临床试验解决方案”主题演讲，展示了“AI for Science”在新药研发领域的生动实践。依托自主研发的医疗大模型，医渡科技打造了覆盖临床研究全场景的智能工具矩阵，更构建了贯穿药械全





生命周期的“端到端”智能研发生态，推动行业从“经验主导”的传统模式向“智能重构”创新模式转变，为全球新药研发提供“中国方案”。

The 2025 Future XDC New Drug Conference, themed "In China, For Global", was held in Chengdu. Xu Jiming, Co-founder and CEO of Yidu Tech, was invited to deliver a keynote speech titled “End-to-End Intelligent Clinical Trial Solutions Based on Large Language Models.” His presentation highlighted the practical application of "AI for Science" in the field of drug development. Powered by its self-developed medical large language models, Yidu Tech has built a comprehensive matrix of intelligent tools that cover all clinical research scenarios. In addition, it has created an end-to-end intelligent R&D ecosystem that spans the entire lifecycle of pharmaceuticals and medical devices. This innovation is helping the industry shift from a traditionally experience-driven model to an AI-reconstructed innovation paradigm, offering a globally relevant "China solution" for new drug development.



医渡科技徐济铭：双中台驱动医疗服务全周期闭环，激活非公医疗“第二曲线”



## **Yidu Tech's Xu Jiming: Dual Middleware Platforms Drive Full-Cycle Healthcare Services, Unlocking the "Second Curve" for Private Healthcare**

中国大健康产业领军人物千人大会暨第五届 GE 医疗博鳌大健康领袖峰会成功举办，海南博鳌乐城国际医疗旅游先行区管理局党委书记、局长贾宁，北大博雅资深教授、北京大学国家发展研究院经济学教授周其仁，清华大学健康中国研究院院长、国家卫健委体制改革司前司长梁万年，GE 医疗中国总裁兼首席执行官张轶昊等千余位业界翘楚齐聚南海之滨，共议非公医疗在新时代的破局之道。

医渡科技联合创始人、CEO 徐济铭受邀出席并发表《AI 中台+DeepSeek 在医疗领域的全场景实践》主题演讲，针对非公立医院面临的增长与质量失衡、患者体验不足等核心痛点，提出以“数据中台+AI 中台”双中台为基座的智能化解决方案，助力医院实现诊前、诊中、诊后全链路闭环服务。

The China Thousand-Person Summit for Leaders in the Health Industry and the 5th GE Healthcare Boao Health Leadership Forum was successfully held. Distinguished guests included Jia Ning, Party Secretary and Director of the Boao Lecheng International Medical Tourism Pilot Zone Administration; Zhou Qiren, Senior Professor at Peking University Boya and Economics Professor at the National School of Development; Liang Wannian, Director of the Institute for Healthy China, Tsinghua University and former Director of the Department of Healthcare Reform at the National Health Commission; and Zhang Yihao, President and CEO of GE Healthcare China. Over a thousand industry leaders gathered on the southern coast to explore breakthroughs for private healthcare in the new era.

Xu Jiming, Co-founder and CEO of Yidu Tech, was invited to attend and delivered a keynote speech titled "AI Middleware Platform + DeepSeek: Full-Scenario Applications in Healthcare." In response to core challenges faced by private hospitals - such as imbalances between growth and quality, and suboptimal patient experiences - he proposed an intelligent solution built on a dual middleware platform structure: a data middleware platform and an AI middleware platform. This approach supports hospitals



in achieving a closed-loop, end-to-end service system covering the pre-diagnosis, diagnosis, and post-diagnosis stages.



医渡科技出席创介高峰论坛，肝癌诊疗智能体“小肝人”受院士推荐

### **Yidu Tech Attended Chuangjie Summit Forum, Liver Cancer AI Agent "Xiao Gan Ren" Recommended by Academician**

由中国健康促进基金会主办、波士顿科学公益支持的“创介高峰论坛”在长沙举行。医渡科技高级副总裁、科研业务线总经理黄楠博士受邀出席并发表《大模型 AI 驱动科研创新与疾病标准化诊疗》主题演讲，充分展示了医渡科技在医疗 AI 领域深厚的技术积淀与科技创新实践能力。

大会主席、中国科学院院士、东南大学医学与生命科学部主任、东南大学附属中大医院介入诊疗中心主任滕皋军教授介绍了与医渡科技联合研发的“小肝人”肝癌智能体。他表示，在实际应用场景中，“小肝人”已获得良好反馈，切实为患者和医生提供了帮助，并希望能和介入界的同仁们紧密合作，以“小肝人”为突破口，将智能诊疗技术推广到肝炎、脂肪肝、肝癌等整个肝病领域，为肝脏疾病防治带来新的变革。



The Chuangjie Summit Forum, hosted by the China Health Promotion Foundation and supported by Boston Scientific, was held in Changsha. Dr. Huang Nan, Senior Vice President of Yidu Tech and General Manager of the Research Business Line, was invited to attend and delivered a keynote speech titled "Large Language Model AI Driving Scientific Innovation and Standardized Diagnosis and Treatment of Diseases," fully demonstrating Yidu Tech's strong technical foundation and practical innovation capabilities in the field of medical AI.

Professor Teng Gaojun, Chairman of the conference, Academician of the Chinese Academy of Sciences, Director of the Southeast University Medicine and Life Sciences, and Director of the Interventional Diagnosis and Treatment Center at Zhongda Hospital Southeast University, introduced the liver cancer AI agent "Xiao Gan Ren", jointly developed with Yidu Tech. He stated that in real application scenarios, "Xiao Gan Ren" has received positive feedback and has truly helped patients and doctors. He expressed hope to work closely with peers in the interventional community, using "Xiao Gan Ren" as a breakthrough to promote intelligent diagnosis and treatment technologies across the entire field of liver diseases - including hepatitis, fatty liver, and liver cancer - bringing new changes to the prevention and treatment of liver diseases.





医渡科技出席 dTrial 2025，大模型助患者招募准确率飙升超 3 倍



## **Yidu Tech Attended dTrial 2025, Large Language Models Triple Accuracy in Patient Recruitment**

第六届数字临床试验创新论坛（dTrial Forum 2025）在北京举办。医渡科技生命科学事业部智能临床试验负责人郝原带来了一场题为《AI 赋能临床研究：患者招募和数据管理》的精彩演讲。医渡科技基于自研医疗大模型，在临床研究患者招募与数据管理领域实现突破性创新。随着 AI 技术迭代升级，公司将持续深化大模型在临床试验全流程的应用，引领行业智能转型。

The 6th Digital Clinical Trial Innovation Forum (dTrial Forum 2025) was held in Beijing. Hao Yuan, Head of Intelligent Clinical Trials at Yidu Tech's Life Sciences Division, delivered a keynote speech titled "AI Empowering Clinical Research: Patient Recruitment and Data Management." Leveraging its self-developed medical large language model, Yidu Tech has achieved breakthrough innovations in patient recruitment and data management for clinical research. As AI technology continues to evolve, the company will further advance the application of large language models throughout the entire clinical trial process, driving intelligent transformation across the industry.





医渡科技出席 CACA 西南产学研大会，AI 中台破解医院智能化应用难题

**Yidu Tech Attended CACA Southwest Industry-Academia-Research Conference,  
AI Middleware Platform Solves Challenges in Hospital Intelligence Applications**

由中国抗癌协会主办，重庆大学附属肿瘤医院承办的“2025CACA 西南产学研大会”在重庆举办。医渡科技政医事业部技术创新副总裁、AI 架构师李林峰博士受邀参会，分享了医疗大模型技术从概念逐步走向临床的实践的医渡经验。他指出，AI 若要真正融入医疗体系，不仅需要技术研发更贴合临床真实需求，还需构建起覆盖数据治理、模型训练、安全应用的全链路解决方案。医渡科技以“AI 医疗大脑”YiduCore 为核心，打造了 AI 中台，为医疗机构数字化转型提供破局之道。

The 2025 CACA Southwest Industry-Academia-Research Conference, hosted by the China Anti-Cancer Association and organized by Chongqing University Cancer Hospital, was held in Chongqing. Dr. Li Linfeng, Vice President of Technology Innovation for Yidu Tech's Government & Healthcare Division and AI Architect, was invited to attend and shared Yidu Tech's practical experience in bringing medical large language model technologies from concept to clinical application. He emphasized that for AI to truly integrate into the healthcare system, it must go beyond technical development and align closely with real clinical needs. It also requires a full-chain solution encompassing data governance, model training, and secure application. Centered around its "AI Medical Brain" YiduCore, Yidu Tech has built an AI middleware platform that offers a breakthrough path for the digital transformation of healthcare institutions.



## 业务进展

### Business Progress

370 万字的指南如何秒级解码？医渡科技助力北肿打造“CACA 指南助手”

**How Can a 3.7-Million-Word Guideline Be Decoded in Seconds? Yidu Tech Helps Beijing Cancer Hospital Launch the "CACA Guideline Assistant"**

医渡科技携手北京大学肿瘤医院（以下简称“北肿”）联合接入中国抗癌协会《中国肿瘤整合诊治指南》（简称《CACA 指南》），成功研发并落地 AI 智能体——CACA 指南助手。该智能体依托 DeepSeek 与医渡科技核心算法引擎 YiduCore，深度融合权威诊疗指南与人工智能技术，实现智能体与医院 HIS、电子病历等院内业务系统的无缝对接，就像肿瘤诊疗领域的“智能导航系统”，帮助医生在复杂的医学指南中快速找到最佳诊疗路径，标志着肿瘤防治进一步迈入“数据智能驱动”新阶段。



Yidu Tech has partnered with Beijing Cancer Hospital (referred to as "BCH") to integrate the China Anti-Cancer Association's Guidelines for Integrated Diagnosis and Treatment of Cancer (CACA Guidelines) and successfully develop and implement an AI agent - the CACA Guideline Assistant. Powered by DeepSeek and Yidu Tech's core algorithm engine, YiduCore, this AI agent deeply integrates authoritative clinical guidelines with advanced artificial intelligence technology. It seamlessly connects with hospital systems such as HIS and electronic medical records, functioning like an "intelligent navigation system" for oncology. The tool helps doctors quickly identify the optimal treatment path within complex medical guidelines, marking a new stage in cancer prevention and treatment driven by data intelligence.

**2025 年度“深圳惠民保”正式上线！医渡科技连续三年担任主运营**

### **2025 "Shenzhen Huimin Insurance" Officially Launched! Yidu Tech Serves as Primary Operator for the Third Consecutive Year**

4 月 22 日，2025 年度“深圳惠民保”新闻发布会顺利召开，深圳市医疗保障局、深圳市地方金融管理局、国家金融监督管理总局深圳监管局、“深圳惠民保”承保机构等相关领导和嘉宾出席了会议。医渡科技已连续三年担任主运营平台。截至目前，医渡科技深度参与了北京、深圳等 4 省 12 市“惠民保”项目的开发和运营，累计服务参保用户超 3400 万人次，为万千家庭带去了保障。

On April 22, the press conference for the 2025 "Shenzhen Huimin Insurance" was successfully held. Officials and guests from the Healthcare Security Bureau of Shenzhen Municipality, Shenzhen Local Financial Supervision Bureau, Shenzhen Office of the National Financial Regulatory Administration, and the program's underwriting institutions attended the event. Yidu Tech has served as the primary operations platform for three consecutive years. To date, Yidu Tech has been deeply involved in the development and operation of Huimin Insurance projects across 4





provinces and 12 cities, including Beijing and Shenzhen, providing services to over 34 million insured users, and delivering protection to millions of families.



医渡科技中标天津市眼科医院科研大数据平台项目

## Yidu Tech Wins Bid for Tianjin Eye Hospital Scientific Research Big Data Platform Project

该院是百年历史的公立三级甲等眼科专科医院，也是医渡科技在天津市合作的第二家眼科专科医院。此前，医渡科技与天津医科大学眼科医院共同打造了天津市眼部疾病临床医学研究中心大数据平台。此次中标进一步巩固了医渡科技在眼科领域的优势，将在天津市形成更好的示范效应。

Tianjin Eye Hospital, a public Class A tertiary specialty hospital with a history of over a century, becomes the second eye specialty hospital in Tianjin to collaborate with Yidu Tech. Previously, Yidu Tech partnered with Tianjin Medical University Eye Hospital to jointly build the Tianjin Eye Disease Clinical Medical Research Center Big



Data Platform. This successful bid further strengthens Yidu Tech's position in the ophthalmology field and is expected to create a stronger demonstration effect within Tianjin.

## 集团荣誉

### Honors of Yidu Tech

喜讯！医渡科技再度获评新财富“最佳 IR 港股公司”

### **Good News! Yidu Tech Once Again Named "Best IR Hong Kong-listed Company" by New Fortune**

第八届新财富最佳 IR 港股公司获奖名单揭晓，医渡科技成功获评，标志着资本市场及投资界对其公司治理能力、投资者关系管理水平及长期价值的深度认可。这已是医渡科技第二次获评该奖项，并且是 AI 医疗赛道唯一入选企业。

The winners of the 8th New Fortune Best IR Hong Kong-listed Companies have been announced, and Yidu Tech has once again been recognized. This award reflects the capital market's and investment community's strong recognition of the company's corporate governance, investor relations management, and long-term value. This marks the second time Yidu Tech has received this honor, and it is the only company in the AI healthcare sector to be selected.

## 最佳IR港股公司(H股)

证券代码	证券简称
01361.HK	361度
01070.HK	TCL电子
02666.HK	环球医疗
03896.HK	金山云
02228.HK	晶泰控股
00135.HK	昆仑能源
00909.HK	明源云
01475.HK	日清食品
01530.HK	三生制药
06969.HK	思摩尔国际
02602.HK	万物云
09868.HK	小鹏汽车-W
03800.HK	协鑫科技
09885.HK	药师帮
02158.HK	医渡科技
03709.HK	赢家时尚
01952.HK	云顶新耀-B
00081.HK	中国海外宏洋集团
00552.HK	中国通信服务
00934.HK	中石化冠德



投资者交流

## Investor Communication

国金证券首次覆盖医渡科技给予买入评级，目标价 7 港元

### **Sinolink Securities Initiates Coverage on Yidu Tech with a "Buy" Rating and Target Price of HKD 7**

国金证券日前发布医渡科技首次覆盖研究报告，指出其在 AI 医疗领域的核心优势及增长潜力，基于 AI 中台产品的加速推广及行业领先的数据治理能力，给予“买入”评级，目标价 7 港元。

Sinolink Securities recently released its initial coverage report on Yidu Tech, highlighting the company's core strengths and growth potential in the AI healthcare sector. Citing the accelerated adoption of its AI middleware platform products and its industry-leading data governance capabilities, the firm assigned a "Buy" rating with a target price of HKD 7.

东北证券首次覆盖医渡科技，YiduCore、DeepSeek 双引擎驱动医疗 AI 生态化

### **Northeast Securities Initiates Coverage on Yidu Tech: YiduCore and DeepSeek Dual Engines Driving an AI-Powered Healthcare Ecosystem**

东北证券发布研报，首次覆盖医渡科技，并给予“增持”评级。东北证券认为，医渡科技在多领域积极布局，展现出强大的行业引领力，近期将 YiduCore 与 DeepSeek 等技术深度融合，全面赋能医疗场景。

Northeast Securities has released a research report, initiating coverage on Yidu Tech with a "Buy" rating. The firm believes that Yidu Tech is actively expanding across multiple sectors, demonstrating strong industry leadership. Recently, the company has



deeply integrated technologies such as YiduCore and DeepSeek, providing comprehensive empowerment across various healthcare scenarios.

**建银国际首次覆盖医渡科技，给予“优于大市”评级**

**CCB International Initiates Coverage on Yidu Tech with "Outperform" Rating**

建银国际发布研报，首次覆盖医渡科技并给予“优于大市”评级，目标价 6.75 港元。研报中指出，中国政府对 AI 医疗的支持力度持续加码，医渡科技在 AI 医疗技术领域已经有自研核心医院管理系统产品，将会直接受益于中国医院群体加速采用人工智能技术的趋势。

CCB International has released a research report initiating coverage on Yidu Tech with an "Outperform" rating and a target price of HKD 6.75. The report notes that the Chinese government is steadily increasing its support for AI in healthcare, and Yidu Tech, with its self-developed core hospital management system in the AI medical technology sector, is well-positioned to benefit directly from the accelerating adoption of AI technologies by hospitals across China.